Insulin-resistant MDA-MB231 human breast cancer cells contain a tyrosine kinase inhibiting activity.
Author(s) -
Angela Costantino,
G Milazzo,
Francesco Giorgino,
P. Russo,
I D Goldfine,
Riccardo Vigneri,
Antonino Belfiore
Publication year - 1993
Publication title -
molecular endocrinology
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1944-9917
pISSN - 0888-8809
DOI - 10.1210/mend.7.12.8145772
Subject(s) - biology , tyrosine kinase , receptor tyrosine kinase , insulin receptor , cancer research , irs2 , endocrinology , insulin , medicine , proto oncogene tyrosine protein kinase src , microbiology and biotechnology , biochemistry , kinase , receptor , insulin resistance
In most human breast cancer cell lines, insulin, via its own receptor, stimulates cell growth. However, in MDA-MB231 breast cancer cells, insulin at concentration as high as 100 nM has no effect on cell growth, although insulin receptors (IRs) are overexpressed in these cells (29.1 ng IR/10(6) cells), and IR binding characteristics are similar to other breast cancer cell lines. IR tyrosine kinase activity is markedly reduced both in intact MDA-MB231 cells and in isolated IRs purified on a wheat germ agglutinin affinity column. MDA-MB231 cells contain a factor that inhibits both basal and insulin-stimulated IR tyrosine kinase activity in a concentration-dependent manner. This inhibitory activity copurifies with the IR on insulin-Sepharose affinity chromatography and is also effective against the tyrosine kinase activity of the IR-related insulin-like growth factor-I receptor and the oncoprotein v-abl but is ineffective against c-src tyrosine kinase activity. It is possible, therefore, that this tyrosine kinase inhibitor plays a role in regulating the mitogenic potential of the IR in some human breast cancers.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom